CV Sciences, Inc.
http://cvsciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CV Sciences, Inc.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Swiss R&D Innovation: A Tale Of Two Firms Developing Cell Therapies For Wounds
While perhaps best known for historical achievements in immuno-oncology and CNS disorders, the Swiss biotech sector is slowly cultivating a new area of expertise in dermatology. Scrip spoke with two firms applying cell therapy technologies to the challenging area of chronic and acute wounds.
Deals Update (05/2007)
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
AF Ablation: Progress & Promise
Tremendous progress has been made in the field of ablation therapy for atrial fibrillation (AF) over the past several years, and numerous device-based technologies to address this underserved and rapidly growing patient population are under clinical development. Minimally invasive, percutaneous AF ablation has evolved rapidly as well, although the procedure remains very challenging and limited to highly experienced centers.
Company Information
- Industry
- Distributors
-
Medical Devices
- Laser
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Canabine
- CannaVest
- CanX Inc
- Foreclosure Solutions, Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice